S100P is an early developmental marker of pancreatic carcinogenesis
S100P is an early developmental marker of pancreatic carcinogenesis
复制标题
DOI：
10.1158/1078-0432.ccr-06-0298
复制
发表时间：
2006-09-15
影响因子：
11.5
通讯作者：
Tanaka, Masao
中科院分区：
文献类型：
--
作者：
Ohuchida, Kenoki;Mizumoto, Kazuhiro;Tanaka, Masao
目的：我们的目标是阐明 S100P 在胰腺癌发生中的参与和临床意义。实验设计：我们检测了 45 个大体胰腺组织中的 S100P 表达；显微切割细胞，包括浸润性导管癌（IDC）细胞（20个切片）、胰腺上皮内瘤变（PanIN）细胞（12个切片）、导管内乳头状粘液性肿瘤（IPMN）细胞（19个切片）和正常上皮细胞（11个切片）；以及来自 99 名胰腺疾病患者的胰液样本（32 名癌症样本、35 名 IPMN 样本和 32 名慢性胰腺炎样本）。我们使用定量实时逆转录 PCR 和基因特异性引发来测量这些不同类型样品中的 S100P。 结果：在大量组织分析中，胰腺癌和 IPMN 表达的 S100P 水平显着高于非肿瘤性胰腺（分别为 P < 0.017 和 P = 0.0013）。显微解剖分析显示，IPMN 的 S100P 表达水平显着高于 IDC (P < 0.0001) 和 PanIN (P = 0.0031)，尽管 IDC 和 PanIN 之间的 S100P 表达没有差异 (P = 0.077)。在胰液分析中，癌症和 IPMN 液表达的 S100P 水平显着高于胰腺炎液（均 P < 0.0001）。受试者工作特征曲线分析显示，胰液中 S100P 的测量有助于区分肿瘤性疾病和慢性胰腺炎（曲线下面积 = 0.837；95% 置信区间，0.749-0.903）。结论：S100P 可能是胰腺癌发生的早期发展标志物，胰液中 S100P 的测量可能有助于早期发现胰腺癌或筛查早期胰腺癌。致癌作用。
Purpose: Our goal was to clarify the involvement and clinical significance of S100P in pancreatic carcinogenesis.Experimental Design: We examined S100P expression in 45 bulk pancreatic tissues; in microdissected cells, including invasive ductal carcinoma (IDC) cells (20 sections), pancreatic intraepithelial neoplasia (PanIN) cells (12 sections), intraductal papillary mucinous neoplasm (IPMN) cells (19 sections), and normal epithelial cells (11 sections); and in pancreatic juice samples from 99 patients with pancreatic diseases (32 cancer, 35 IPMN, and 32 chronic pancreatitis samples). We used quantitative real-time reverse transcription-PCR with gene-specific priming to measure S100P in these various types of samples.Results: In bulk tissue analyses, pancreatic cancer and IPMN expressed significantly higher levels of S100P than did nonneoplastic pancreas (P < 0.017 and P = 0.0013, respectively). Microdissection analyses revealed that IPMN expressed significantly higher levels of S100P than did IDC (P < 0.0001) and PanIN (P = 0.0031), although S100P expression did not differ between IDC and PanIN (P = 0.077). In pancreatic juice analyses, cancer and IPMN juice expressed significantly higher levels of S100P than did pancreatitis juice (both P < 0.0001). Receiver operating characteristic curve analyses revealed that measurement of S100P in pancreatic juice was Useful for discriminating neoplastic disease from chronic pancreatitis (area under the curve = 0.837; 95% confidence interval, 0.749-0.903).Conclusion: S100P may be an early developmental marker of pancreatic carcinogenesis, and measurement of S100P in pancreatic juice may be useful for early detection of pancreatic cancer or screening of early pancreatic carcinogenesis.